Short answer
“Prozac Weekly” was a once‑weekly oral formulation of fluoxetine that was approved by the FDA but never really made it onto the market. Pfizer decided to pull the plug because the drug offered no clear medical or commercial advantage over the standard daily fluoxetine tablets, and the expected sales were too low to justify the cost of marketing, manufacturing, and reimbursement negotiations.
---
What “Prozac Weekly” actually was
| Feature | Detail |
|---------|--------|
| Drug | Fluoxetine (the active ingredient in Prozac®) |
| Dosage | 75 mg taken once a week (≈10 mg per day equivalent) |
| Intended benefit | Easier adherence for patients who struggle with daily dosing; smoother plasma concentrations to reduce peak‑trough side‑effects. |
| Approval | FDA approved it in 2010 (label: “Prozac Weekly”, brand name Prozac Weekly) for adults with major depressive disorder. |
| Availability | Only a handful of pharmacies stocked it, and it was never launched in the United States at full scale. |
Why it was discontinued
1. Limited commercial opportunity
- The U.S. market for fluoxetine is already saturated with daily tablets that are inexpensive and widely used.
- The weekly formulation would have been priced higher, but reimbursement agencies (Medicare, Medicaid, insurers) were reluctant to cover it.
2. No clear clinical advantage
- Clinical studies did not show a significant benefit in terms of efficacy, safety, or patient adherence compared to standard daily dosing.
- The longer dosing interval meant higher peak plasma concentrations after each dose, which could potentially increase side‑effects in some patients.
3. Marketing & manufacturing costs
- Pfizer had to invest in a separate manufacturing line, marketing campaign, and distribution network for a product that was unlikely to generate sufficient sales volume.
- The cost of bringing a new dosage form to market is high; the projected return did not justify the investment.
4. Regulatory & reimbursement hurdles
- Because the drug was essentially a reformulation, insurers treated it as a “new drug” and required separate negotiations.
- The lack of a strong payer strategy meant that many patients would not receive coverage, limiting adoption.
5. Strategic focus
- Pfizer decided to concentrate resources on its core portfolio (the daily fluoxetine tablets and other antidepression products) rather than a niche once‑weekly product.
Bottom line
There were no safety problems that forced the drug off the shelves; it was simply not a viable business. The drug’s limited clinical benefit and poor commercial prospects led Pfizer to stop marketing it. For most patients, the standard daily fluoxetine tablets remain the most effective and accessible option. If you or someone you know is having trouble sticking to daily medication, it’s worth discussing alternative strategies (e.g., different antidepressants, adherence tools, or other supportive therapies) with a healthcare provider.